You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoexipril
Accession NumberDB00691  (APRD01120)
TypeSmall Molecule
GroupsApproved
Description

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Structure
Thumb
Synonyms
Moexipril
Moexiprilum
Uniretic
Univasc
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Univasctablet, film coated7.5 mg/1oralUCB, Inc.1995-07-152016-04-23Us
Univasctablet, film coated15 mg/1oralUCB, Inc.1995-07-152016-02-25Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-312016-04-05Us
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralTeva Pharmaceuticals USA Inc2003-05-082016-04-23Us
Moexipril Hydrochloridetablet, film coated15 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-312016-04-05Us
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralCarilion Materials Management2003-05-082016-04-05Us
Moexipril Hydrochloridetablet15 mg/1oralApotex Corp.2008-06-092016-04-05Us
Moexipril Hydrochloridetablet7.5 mg/1oralApotex Corp.2008-06-092016-04-05Us
Moexipril Hydrochloridetablet7.5 mg/1oralPhysicians Total Care, Inc.2008-08-142016-04-05Us
Moexipril Hydrochloridetablet15 mg/1oralPhysicians Total Care, Inc.2004-04-272016-04-05Us
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralAvera Mc Kennan Hospital2015-08-102016-04-05Us
Moexipril Hydrochloridetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2003-05-082016-04-23Us
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Moexipril Hydrochloride and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Salts
Name/CASStructureProperties
Moexipril Hydrochloride
Thumb
  • InChI Key: JXRAXHBVZQZSIC-JKVLGAQCSA-N
  • Monoisotopic Mass: 534.213279191
  • Average Mass: 535.029
DBSALT000504
Categories
UNIIWT87C52TJZ
CAS number103775-10-6
WeightAverage: 498.5681
Monoisotopic: 498.236601452
Chemical FormulaC27H34N2O7
InChI KeyInChIKey=UWWDHYUMIORJTA-HSQYWUDLSA-N
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[[email protected]]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Mechanism of actionMoexipril is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone). Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension.
Related Articles
AbsorptionMoexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.
Volume of distribution
  • 183 L
Protein bindingMoexiprilat is approxomately 50% protein bound.
Metabolism

Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.

SubstrateEnzymesProduct
Moexipril
Not Available
MoexiprilatDetails
Route of eliminationMoexiprilat undergoes renal elimination.
Half lifeMoexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.
Clearance
  • 441 mL/min
ToxicityHuman overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Moexipril Metabolism PathwayDrug metabolismSMP00595
Moexipril Action PathwayDrug actionSMP00151
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5775
Blood Brain Barrier-0.9022
Caco-2 permeable-0.7313
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.5919
P-glycoprotein inhibitor IIInhibitor0.8157
Renal organic cation transporterNon-inhibitor0.8146
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.8369
CYP450 3A4 substrateSubstrate0.7014
CYP450 1A2 substrateNon-inhibitor0.8205
CYP450 2C9 inhibitorNon-inhibitor0.5961
CYP450 2D6 inhibitorNon-inhibitor0.8261
CYP450 2C19 inhibitorNon-inhibitor0.6592
CYP450 3A4 inhibitorNon-inhibitor0.5935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6861
Ames testNon AMES toxic0.8358
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity2.5131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9715
hERG inhibition (predictor II)Inhibitor0.8751
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Glenmark generics ltd
  • Paddock laboratories inc
  • Teva pharmaceuticals usa inc
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral7.5 mg/1
Prices
Unit descriptionCostUnit
Univasc 15 mg tablet2.44USD tablet
Univasc 7.5 mg tablet2.13USD tablet
Moexipril hcl 15 mg tablet1.48USD tablet
Moexipril hcl 7.5 mg tablet1.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00585 mg/mLALOGPS
logP1.52ALOGPS
logP1.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.46ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area114.4 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity132.88 m3·mol-1ChemAxon
Polarizability53.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J: Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiol. 2002 Feb;57(1):31-2. [PubMed:11918132 ]
  2. Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME: Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. [PubMed:9825188 ]
  3. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. [PubMed:9617599 ]
  4. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther. 2002 Jan;40(1):9-17. [PubMed:11837383 ]
  5. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  6. Chrysant SG, Chrysant GS: Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. [PubMed:15030263 ]
  7. Chrysant GS, Nguyen PK: Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. [PubMed:17583172 ]
  8. Grass GM, Morehead WT: Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989 Sep;6(9):759-65. [PubMed:2554270 ]
  9. Kalasz H, Petroianu G, Tekes K, Klebovich I, Ludanyi K, Gulyas Z: Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem. 2007 Jan;3(1):101-6. [PubMed:17266629 ]
  10. Persson B, Stimpel M: Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 1996;50(4):259-64. [PubMed:8803515 ]
  11. Spinar J, Vitovec J: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. Int J Cardiol. 2005 Apr 20;100(2):199-206. [PubMed:15823625 ]
  12. Stimpel M, Koch B, Oparil S: Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998 May;89(4):271-6. [PubMed:9643274 ]
  13. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998 May-Jun;18(3):588-99. [PubMed:9620109 ]
  14. White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM: Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995 Mar;35(3):233-8. [PubMed:7608310 ]
External Links
ATC CodesC09AA13C09BA13
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Moexipril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Moexipril.
AliskirenAliskiren may increase the hyperkalemic activities of Moexipril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexipril.
AmifostineMoexipril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Moexipril.
ArdeparinArdeparin may increase the hyperkalemic activities of Moexipril.
AzathioprineMoexipril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Moexipril.
ButabarbitalButabarbital may increase the hypotensive activities of Moexipril.
ButethalButethal may increase the hypotensive activities of Moexipril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Moexipril.
CiprofloxacinMoexipril may increase the arrhythmogenic activities of Ciprofloxacin.
CitalopramMoexipril may increase the QTc-prolonging activities of Citalopram.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Moexipril.
DiazoxideDiazoxide may increase the hypotensive activities of Moexipril.
DofetilideMoexipril may increase the QTc-prolonging activities of Dofetilide.
DrospirenoneMoexipril may increase the hyperkalemic activities of Drospirenone.
DuloxetineMoexipril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Moexipril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.
GoserelinMoexipril may increase the QTc-prolonging activities of Goserelin.
HeparinHeparin may increase the hyperkalemic activities of Moexipril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Moexipril.
HexobarbitalHexobarbital may increase the hypotensive activities of Moexipril.
IcatibantIcatibant may decrease the antihypertensive activities of Moexipril.
InfliximabThe risk or severity of adverse effects can be increased when Moexipril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.
LanthanumThe serum concentration of Moexipril can be decreased when it is combined with Lanthanum.
LeuprolideMoexipril may increase the QTc-prolonging activities of Leuprolide.
LevodopaMoexipril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Moexipril.
MethohexitalMethohexital may increase the hypotensive activities of Moexipril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Moexipril.
MifepristoneMifepristone may increase the QTc-prolonging activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Moexipril.
MoxonidineMoxonidine may increase the hypotensive activities of Moexipril.
NicorandilNicorandil may increase the hypotensive activities of Moexipril.
ObinutuzumabMoexipril may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Moexipril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Moexipril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Moexipril.
PregabalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Moexipril.
QuinineQuinine may increase the hypotensive activities of Moexipril.
RisperidoneMoexipril may increase the hypotensive activities of Risperidone.
RituximabMoexipril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sacubitril.
SecobarbitalSecobarbital may increase the hypotensive activities of Moexipril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Sodium aurothiomalate.
TadalafilTadalafil may increase the antihypertensive activities of Moexipril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Moexipril.
TizanidineTizanidine may increase the hypotensive activities of Moexipril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Moexipril.
TorasemideTorasemide may increase the hypotensive activities of Moexipril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Moexipril.
TreprostinilTreprostinil may increase the hypotensive activities of Moexipril.
TriamtereneTriamterene may increase the hyperkalemic activities of Moexipril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Moexipril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Moexipril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.
VardenafilVardenafil may increase the antihypertensive activities of Moexipril.
YohimbineYohimbine may decrease the antihypertensive activities of Moexipril.
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of moexipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of moexipril.
  • Moexipril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take moexipril one hour before or two hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function.(Microbial infection) Acts as a receptor for SARS coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
Gene Name:
ACE2
Uniprot ID:
Q9BYF1
Molecular Weight:
92462.4 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11